Boston, Massachusetts 02114


Purpose:

This clinical trial examines whether nasal theophylline administration can improve olfaction and nutrition in hemodialysis patients.


Study summary:

Malnutrition and cachexia are prevalent in end stage renal disease (ESRD) patients and are associated with increased morbidity and mortality. Food aversion is a major contributor to anorexia and malnutrition in ESRD and it also impacts the quality of life. Olfactory dysfunction has been shown to contribute to food aversion in ESRD patients. Since up to 80% of a meal's flavor is attributed to olfactory input, loss or alteration of smell leads to loss or alteration of taste in ESRD patients and at present there are no effective therapies to treat smell and/or taste disorders in ESRD patients. In patients with other causes of olfactory dysfunction such as congenital hyposmia and traumatic brain injury, intranasal theophylline has been shown to be effective in improving olfactory defects via increasing nasal mucus levels of cAMP and cGMP, second messengers critical for optimal smell sensation. However, the efficacy of nasal theophylline to improve olfaction in ESRD patients has not been investigated and the effects of nasal theophylline treatment on the nutritional parameters are unknown in ESRD patients. Aim: To examine the efficacy and safety of nasal theophylline treatment to improve olfaction and nutrition in ESRD patients Hypothesis: Nasal theophylline treatment improves olfaction and nutrition in ESRD patients with olfactory defects by via increasing intracellular cAMP and cGMP levels. A previous pilot clinical trial demonstrated that intranasal theophylline is safe and effective in improving olfactory deficits in congenital hyposmia and traumatic brain injury, however, it has not been examined in ESRD patients. The investigators will conduct a pilot single arm open-label clinical trial (n=20) of 6 weeks duration to examine the efficacy and safety of nasal theophylline in hemodialysis-dependent ESRD patients with olfactory defects. The investigators will examine whether nasal theophylline improves olfaction and nutritional status in trial participants.


Criteria:

Inclusion Criteria: - ESRD requiring chronic outpatient hemodialysis - Able to provide written consent - Defects in smell identification and/or smell threshold detection as measured by "Scratch-and-sniff" University of Pennsylvania Smell Identification Test (UPSIT) and Smell Threshold Test Exclusion Criteria: - Prior allergic reaction to theophylline - Patients currently treated with theophylline for clinical indication - Pregnancy or lactation - ESRD patients on peritoneal dialysis - Patients hospitalized at the time of study enrollment


NCT ID:

NCT02479451


Primary Contact:

Principal Investigator
Sagar U Nigwekar, MD, MMSc
Massachusetts General Hospital

Sagar U. Nigwekar, MD, MMSc
Phone: 617 726 7872
Email: snigwekar@mgh.harvard.edu


Backup Contact:

Email: tpaunescu@mgh.harvard.edu
Teodor G. Paunescu, PhD
Phone: 617 726 3696


Location Contact:

Boston, Massachusetts 02114
United States

Sagar Nigwekar, MD, MMSc
Phone: 617-726-7872
Email: snigwekar@mgh.harvard.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.